Trial Profile
Phase 1 Study to Evaluate Safety, and Preliminary Efficacy of Pasireotide LAR in Castration Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 28 Mar 2019 Status changed from active, no longer recruiting to completed.
- 06 May 2017 Planned End Date changed from 1 Jun 2017 to 30 Sep 2018.
- 06 May 2017 Planned primary completion date changed from 1 Jun 2017 to 30 Sep 2018.